Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction
- PMID: 24859607
- DOI: 10.1016/j.neuropharm.2014.05.007
Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction
Abstract
Glycyrrhizin (GL) is a major constituent of licorice root and has been suggested to inhibit the release of high mobility group box-1 (HMGB1), a protein considered representative of damage-associated molecular patterns. We found that GL bound HMGB1 but not RAGE with a moderate equilibrium dissociation constant value based on surface plasmon resonance analysis. This complex formation prevented HMGB1 from binding to RAGE in vitro. The effects of glycyrrhizin on traumatic brain injury (TBI) induced by fluid percussion were examined in rats or mice in the present study. GL was administered intravenously after TBI. Treatment of rats with GL dose-dependently suppressed the increase in BBB permeability and impairment of motor functions, in association with the inhibition of HMGB1 translocation in neurons in injured sites. The beneficial effects of GL on motor and cognitive functions persisted for 7 days after injury. The expression of TNF-α, IL-1β and IL-6 in injured sites was completely inhibited by GL treatment. In RAGE-/- mice, the effects of GL were not observed. These results suggested that GL may be a novel therapeutic agent for TBI through its interference with HMGB1 and RAGE interaction.
Keywords: Brain edema; Glycyrrhizin; HMGB1; RAGE; Traumatic brain injury.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Anti-high mobility group box-1 antibody therapy for traumatic brain injury.Ann Neurol. 2012 Sep;72(3):373-84. doi: 10.1002/ana.23602. Epub 2012 Aug 22. Ann Neurol. 2012. PMID: 22915134
-
Effect of glycyrrhizin on traumatic brain injury in rats and its mechanism.Chin J Traumatol. 2014;17(1):1-7. Chin J Traumatol. 2014. PMID: 24506915
-
Is genistein neuroprotective in traumatic brain injury?Physiol Behav. 2015 Dec 1;152(Pt A):26-31. doi: 10.1016/j.physbeh.2015.08.037. Epub 2015 Sep 11. Physiol Behav. 2015. PMID: 26367454
-
An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.Pharmacol Ther. 2014 Mar;141(3):347-57. doi: 10.1016/j.pharmthera.2013.11.001. Epub 2013 Nov 9. Pharmacol Ther. 2014. PMID: 24220159 Review.
-
Glycyrrhizin, a Potential Drug for Autoimmune Encephalomyelitis by Inhibiting High-Mobility Group Box 1.DNA Cell Biol. 2018 Dec;37(12):941-946. doi: 10.1089/dna.2018.4444. Epub 2018 Oct 16. DNA Cell Biol. 2018. PMID: 30325653 Review.
Cited by
-
Therapeutic Potential of Targeting the HMGB1/RAGE Axis in Inflammatory Diseases.Molecules. 2022 Oct 27;27(21):7311. doi: 10.3390/molecules27217311. Molecules. 2022. PMID: 36364135 Free PMC article. Review.
-
Neuroinflammation of traumatic brain injury: Roles of extracellular vesicles.Front Immunol. 2023 Jan 18;13:1088827. doi: 10.3389/fimmu.2022.1088827. eCollection 2022. Front Immunol. 2023. PMID: 36741357 Free PMC article. Review.
-
The Role of HMGB1 in Traumatic Brain Injury-Bridging the Gap Between the Laboratory and Clinical Studies.Curr Neurol Neurosci Rep. 2021 Dec 6;21(12):75. doi: 10.1007/s11910-021-01158-3. Curr Neurol Neurosci Rep. 2021. PMID: 34870759 Review.
-
High Mobility Group Box-1 and Blood-Brain Barrier Disruption.Cells. 2020 Dec 10;9(12):2650. doi: 10.3390/cells9122650. Cells. 2020. PMID: 33321691 Free PMC article. Review.
-
The Emerging Role of HMGB1 in Neuropathic Pain: A Potential Therapeutic Target for Neuroinflammation.J Immunol Res. 2016;2016:6430423. doi: 10.1155/2016/6430423. Epub 2016 May 18. J Immunol Res. 2016. PMID: 27294160 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources